← Back to Search

Tau PET Imaging for Cognitive Impairment

Phase 2

Waitlist Available

Led By Neill R Graff-Radford

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is studying how well different types of brain scans work in people of different races who have either no memory problems or mild memory problems.

Who is the study for?

This trial is for African American adults aged 30 or older who have either normal cognitive function or dementia. They must be able to lie still for 20 minutes and not have conditions like a prolonged QT interval on an ECG, metal implants, pacemakers, or severe claustrophobia that would prevent MRI scans.Check my eligibility

What is being tested?

The study is examining the use of Tau PET scans in African Americans to understand more about brain imaging tests across different races in people with normal cognition or dementia.See study design

What are the potential side effects?

There are generally no significant side effects associated with undergoing a Tau PET scan itself; however, some individuals may experience discomfort from lying still during the procedure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Radionuclide Imaging

Trial Design

3Treatment groups

Experimental Treatment

Group I: Normal controlExperimental Treatment1 Intervention

Cognitively normal volunteers

Group II: Mild Cogntive impairmentExperimental Treatment1 Intervention

Person with cognitive impairment that meet Peterson Criteria

Group III: DementedExperimental Treatment1 Intervention

Patient's that meet dementia criteria

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,206 Previous Clinical Trials

3,766,843 Total Patients Enrolled

National Institute on Aging (NIA)NIH

1,669 Previous Clinical Trials

28,004,874 Total Patients Enrolled

Neill R Graff-RadfordPrincipal InvestigatorMayo Clinic

1 Previous Clinical Trials

9 Total Patients Enrolled

Media Library

Tau PET scan Clinical Trial Eligibility Overview. Trial Name: NCT03618186 — Phase 2

Cognitive Impairment Research Study Groups: Normal control, Mild Cogntive impairment, Demented

Cognitive Impairment Clinical Trial 2023: Tau PET scan Highlights & Side Effects. Trial Name: NCT03618186 — Phase 2

Tau PET scan 2023 Treatment Timeline for Medical Study. Trial Name: NCT03618186 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA given clearance for Tau PET scans?

"Due to the fact that this clinical trial is only in its second phase, there are some safety data available but none on efficacy yet. As a result, Tau PET Scan was assigned a rating of 2 out of 3."

Answered by AI

Are there any openings in this investigation at the present time?

"Clinicaltrials.gov confirms that this trial, initially posted on November 26th 2018 and last updated on January 31st 2022, is not searching for participants currently. However, over 600 other trials are actively enrolling patients to participate in their studies."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Tau PET Imaging in African Americans

Neill R. Graff-Radford, M.D. 2018. "Tau PET Imaging in African Americans". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03618186.